Cybin Inc. Common Stock
HELP
Rangering i aksjer
#11639
Cybin Inc. functions as a biopharmaceutical company currently in its clinical... Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
Aksjekurs
$10.30
Sist synkronisert: 2026-08-11
Markedsverdi
$638.32M
Endring (1 dag)
2.88%
Endring (1 år)
9,119.52%
Land
CA
Handel Cybin Inc. Common Stock (HELP)
Kategori
Healthcare
EPS for Cybin Inc. Common Stock (HELP)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Cybin Inc. Common Stock er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Cybin Inc. Common Stock fra 2026 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| Ikke nok data for de angitte datoene. | ||
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| - | - |
CH
|
|
| $27.74 | - |
NL
|
